Feb 28, 2023 / 04:00PM GMT
Arthur He - H.C. Wainwright & Co., LLC - Analyst
Good morning, and thanks for joining us at H.C. Wainwright's Cell Therapy Conference to have a conversation with Mr. Mark Gergen, the Chief Executive Officer of Poseida Therapeutics. Poseida is a clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies to treat cancers and the rare genetic diseases.
The company is leveraging its proprietary platforms, including piggyBac, Cas-CLOVER, and the nanoparticle delivery technologies for pipeline development. Poseida currently has two clinical-stage allo CAR-T candidates and a number of preclinical in vivo gene therapy programs.
To discuss these programs and to learn about the company's development strategy in 2023 and beyond, I'd like to invite Mark to this fireside chat. Good morning, Mark.
Mark Gergen - Poseida Therapeutics, Inc. - CEO
Good morning, Arthur. Thanks for having us at the conference today.
Arthur He - H.C. Wainwright & Co., LLC - Analyst
Yeah, glad to
Poseida Therapeutics Inc at HC Wainwright Cell Therapy Virtual Conference Transcript
Feb 28, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers